PURPOSE: Gastric pentadecapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments it is more effective for ulcers and various wounds, and can be used without a carrier needed for other peptides, both locally and systemically (i.e., perorally, parenterally). We studied the effectiveness of BPC 157 for ileoileal anastomosis healing in rats. METHODS: We assessed ileoileal anastomosis dehiscence macroscopically, histologically, and biomechanically (volume [ml] infused through a syringe-perfusion pump system (1 ml/10 s), and pressure [mmHg] to leak induction [catheter connected to a chamber and a monitor, at 10 cm proximal to anastomosis]), at 1, 2, 3, 4, 5, 6, 7, and 14 days. BPC 157 (10 microg, 10 ng, 10 pg/kg i.p. (or saline [5 ml/kg]) was first administered after surgery, while it was last given 24 h before either assessment or sacrifice. RESULTS: Throughout the experiment, both higher doses of BPC 157 were shown to improve all parameters of anastomotic wound healing. The formation of adhesions remained slight, the blood vessels were filled with blood, and a mild intestinal passage obstruction was only temporarily observed. Anastomosis without leakage induces markedly higher volume and pressure values, with a continuous increase toward healthy values. From day 1, edema was markedly attenuated and the number of granulocytes decreased, while from days 4 or 5 necrosis decreased and granulation tissue, reticulin, and collagen formation substantially increased, thus resulting in increased epithelization. CONCLUSION: This study showed BPC 157 to have a beneficial effect on ileoileal anastomosis healing in the rat.
PURPOSE: Gastric pentadecapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments it is more effective for ulcers and various wounds, and can be used without a carrier needed for other peptides, both locally and systemically (i.e., perorally, parenterally). We studied the effectiveness of BPC 157 for ileoileal anastomosis healing in rats. METHODS: We assessed ileoileal anastomosis dehiscence macroscopically, histologically, and biomechanically (volume [ml] infused through a syringe-perfusion pump system (1 ml/10 s), and pressure [mmHg] to leak induction [catheter connected to a chamber and a monitor, at 10 cm proximal to anastomosis]), at 1, 2, 3, 4, 5, 6, 7, and 14 days. BPC 157 (10 microg, 10 ng, 10 pg/kg i.p. (or saline [5 ml/kg]) was first administered after surgery, while it was last given 24 h before either assessment or sacrifice. RESULTS: Throughout the experiment, both higher doses of BPC 157 were shown to improve all parameters of anastomotic wound healing. The formation of adhesions remained slight, the blood vessels were filled with blood, and a mild intestinal passage obstruction was only temporarily observed. Anastomosis without leakage induces markedly higher volume and pressure values, with a continuous increase toward healthy values. From day 1, edema was markedly attenuated and the number of granulocytes decreased, while from days 4 or 5 necrosis decreased and granulation tissue, reticulin, and collagen formation substantially increased, thus resulting in increased epithelization. CONCLUSION: This study showed BPC 157 to have a beneficial effect on ileoileal anastomosis healing in the rat.
Authors: P Sikiric; S Seiwerth; Z Grabarevic; M Petek; R Rucman; B Turkovic; I Rotkvic; V Jagic; M Duvnjak; S Mise Journal: Life Sci Date: 1994 Impact factor: 5.037
Authors: B Sebecić; V Nikolić; P Sikirić; S Seiwerth; T Sosa; L Patrlj; Z Grabarević; R Rucman; M Petek; P Konjevoda; S Jadrijević; D Perović; M Slaj Journal: Bone Date: 1999-03 Impact factor: 4.398
Authors: M Staresinic; B Sebecic; L Patrlj; S Jadrijevic; S Suknaic; D Perovic; G Aralica; N Zarkovic; S Borovic; M Srdjak; K Hajdarevic; M Kopljar; L Batelja; A Boban-Blagaic; I Turcic; T Anic; S Seiwerth; P Sikiric Journal: J Orthop Res Date: 2003-11 Impact factor: 3.494
Authors: Antonija Duzel; Josipa Vlainic; Marko Antunovic; Dominik Malekinusic; Borna Vrdoljak; Mariam Samara; Slaven Gojkovic; Ivan Krezic; Tinka Vidovic; Zdenko Bilic; Mario Knezevic; Marko Sever; Nermin Lojo; Antonio Kokot; Marijan Kolovrat; Domagoj Drmic; Jaksa Vukojevic; Tamara Kralj; Katarina Kasnik; Marko Siroglavic; Sven Seiwerth; Predrag Sikiric Journal: World J Gastroenterol Date: 2017-12-28 Impact factor: 5.742
Authors: Predrag Sikiric; Ki-Baik Hahm; Alenka Boban Blagaic; Ante Tvrdeic; Katarina Horvat Pavlov; Andrea Petrovic; Antonio Kokot; Slaven Gojkovic; Ivan Krezic; Domagoj Drmic; Rudolf Rucman; Sven Seiwerth Journal: Gut Liver Date: 2020-03-15 Impact factor: 4.519